Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

If you’re looking for trail shoes that are lightweight, flashy, and fun, look no more because the Arc’teryx Vertex Speed ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

Vertex Securities Ltd share price was up by 0.44% from the previous closing price of ₹4.57. Who are peers of Vertex Securities Ltd? The peers of Vertex Securities Ltd are Motilal Oswal Financial ...

Mary Jo Cagle, CEO of North Carolina-based health system Cone Health, is stepping down from her role due to a family health matter. She worked at the health system for more than 14 years ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...